Artivion Inc

The medium-term bias is bullish due to Stage 2 mean-reversion eligibility, but recent exhaustion at resistance combined with neutral short-term momentum argues for patience; pullbacks into the rising 20-day EMA and 50-day SMA zone represent structurally favorable entry opportunities, while a decisive close below these EMAs would invalidate the bullish posture.

• ↑Q2 revenue $125.8M (+11% YoY), 4.8% above consensus.
• ↑FDA PMA approval for AMDS expected mid-2026 unlocks new sales.
• ↓Q2 net loss $13.5M (EPS -$0.28) below analyst forecasts.